P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY

• P Rodríguez-Otero,
• J San-Miguel,
• LD Anderson, Jr,
• S Lonial,
• A Truppel-Hartmann,
• J Sanford,
• E Rowe,
• TB Campbell,
• N Munshi

Affiliations

P Rodríguez-Otero

1 Clínica Universidad de Navarra, Pamplona (Spain)

J San-Miguel

1 Clínica Universidad de Navarra, Pamplona (Spain)

LD Anderson, Jr

2 University of Texas Southwestern, Dallas (USA)

S Lonial

3 Emory School of Medicine, Atlanta (USA)

A Truppel-Hartmann

4 2seventybio, Cambridge (USA)

J Sanford

5 Bristol Myers Squibb, Princeton (USA)

E Rowe

5 Bristol Myers Squibb, Princeton (USA)

TB Campbell

5 Bristol Myers Squibb, Princeton (USA)

N Munshi

6 Dana-Farber Cancer Institute, Boston (USA).